This page is an educational summary and does not constitute clinical guidance or a recommendation for use. Prescribing, dosing and treatment decisions should be made on the basis of individual patient assessment, current clinical guidelines and the treating healthcare professional's judgement.
What is CBG?
CBG (C₂₁H₃₂O₂) is a naturally occurring cannabinoid in Cannabis sativa. CBGA (cannabigerolic acid) is the biosynthetic precursor from which THCA, CBDA and CBCA are derived in the cannabis plant. Most CBGA converts to other cannabinoids during maturation, leaving <1% CBG in most varieties. High-CBG cultivars are harvested early.
Pharmacology
CBG acts as a partial CB1 and CB2 agonist (weak), alpha-2 adrenoceptor agonist and 5-HT1A antagonist. It is non-psychoactive. Pharmacological profile is distinct from THC and CBD and less well characterised due to limited clinical research.
Current Evidence
No completed Phase 2/3 RCTs as of 2026. Preclinical evidence suggests potential in IBD, neuroprotection, glaucoma (intraocular pressure) and MRSA. Healthcare professionals should apply caution — commercial claims for CBG substantially exceed the clinical evidence.
GMP Relevance
CBG at low concentrations should be included in cannabinoid profiling specifications. CBG-enriched products require high-CBG cultivar starting material or purification. Method validation should confirm separation of CBG from other cannabinoids.
Regulatory Status
CBG is not independently scheduled as a controlled substance in most European jurisdictions as a component of cannabis starting material. Pharmaceutical preparations require EU GMP manufacturing standards. Specifications should include identity, purity and assay by validated HPLC.
See the Cannabis Glossary for definitions of related cultivation, extraction and quality terms.
References
- Nachnani R et al. The Influence of CBG on Quorum Sensing. Biointerphases. 2021.
- Russo EB. Taming THC. Br J Pharmacol. 2011.